General
Preferred name
ORITAVANCIN
Synonyms
LY333328 diphosphate ()
ORITAVANCIN DIPHOSPHATE ()
Orbactiv ()
Oritavancin (diphosphate) ()
LY333328 ()
LY-333328 ()
Oritavancin phosphate ()
Nuvocid ()
LY333328 DIPHOSPHATE ()
Kimyrsa ()
LY-333328 DIPHOSPHATE ()
Oritavancin (phosphate) ()
P&D ID
PD009348
CAS
192564-14-0
171099-57-3
Tags
available
drug
Approved by
EMA
FDA
First approval
2014
Drug Status
investigational
approved
Drug indication
Bacterial infection
Gram-positive bacterial infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.
DESCRIPTION
Oritavancin is a semi-synthetic glycopeptide antibacterial drug . It is structurally related to vancomycin, and likewise is active against several Gram-positive organisms including methicillin resistant Staphylococcus aureus (MRSA). Like , it offers the option of single-dose administration.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
18
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Other bioactive compounds
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
45
Molecular Weight
1790.56
Hydrogen Bond Acceptors
28
Hydrogen Bond Donors
20
Rotatable Bonds
19
Ring Count
15
Aromatic Ring Count
7
cLogP
4.5
TPSA
560.98
Fraction CSP3
0.42
Chiral centers
22.0
Largest ring
16.0
QED
0.05
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
skin infections
MOA
bacterial cell wall synthesis inhibitor
Biosynthetic Origin
Peptide (NRPS), Carbohydrate (Aminoglycoside)
Therapeutic Indication
Antibacterial
Therapeutic Class
Antimicrobial
Pathway
Anti-infection
Target
antibiotic
Bacterial
Source data
